Crystals of benzimidazole compounds

Abstract

Crystals of (S)-2[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or salts thereof, useful as excellent antiulcer drugs.

1 - 4 . (canceled)  
   
   
       5 . A method for treating or preventing reflux esophagitis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a crystalline compound of (S)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole, its hydrate or a salt thereof.  
   
   
       6 . The method of  claim 5 , wherein said crystalline compound is (S)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole.  
   
   
       7 . The method of  claim 6 , wherein said crystalline compound has a powder X-ray diffraction pattern whose characteristic peaks appear as the lattice spacing (d) of the powder X-ray diffraction at 11.68, 6.78, 5.85, 5.73, 4.43, 4.09, 3.94, 3.90, 3.69, 3.41, 3.11 angstrom.  
   
   
       8 . The method of  claim 5 , wherein said crystalline compound is (S)-2-[[[3 -methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole 1.5 hydrate which has a powder X-ray diffraction pattern whose characteristic peaks appear as the lattice spacing (d) of the powder X-ray diffraction at 13.22, 9.60, 8.87, 8.05, 6.61, 5.92, 5.65, 5.02, 4.50, 3.57, 3.00 angstrom.  
   
   
       9 . A method for eradicating  Helicobacter pylori  in a mammal in need thereof, which comprises administering to said mammal an effective amount of a crystalline compound of (S)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole, its hydrate or a salt thereof.  
   
   
       10 . The method of  claim 9 , wherein said crystalline compound is (S)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole.  
   
   
       11 . The method of  claim 10 , wherein said crystalline compound has a powder X-ray diffraction pattern whose characteristic peaks appear as the lattice spacing (d) of the powder X-ray diffraction at 11.68, 6.78, 5.85, 5.73, 4.43, 4.09, 3.94, 3.90, 3.69, 3.41, 3.11 angstrom.  
   
   
       12 . The method of  claim 9 , wherein said crystalline compound is (S)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole 1.5 hydrate which has a powder X-ray diffraction pattern whose characteristic peaks appear as the lattice spacing (d) of the powder X-ray diffraction at 13.22, 9.60, 8.87, 8.05, 6.61, 5.92, 5.65, 5.02, 4.50, 3.57, 3.00 angstrom.  
   
   
       13 . The method of  claim 9 , further comprising administering one to three other active ingredients.  
   
   
       14 . The method of  claim 13 , wherein said crystalline compound and said other active ingredient are administered simultaneously or in intervals.  
   
   
       15 . The method of  claim 13 , wherein said other active ingredient is selected from the group consisting of an anti-Helicobacter pylori action substance, an imidazole compound, a bismuth salt, a quinoline compound and combinations thereof.  
   
   
       16 . The method of  claim 15 , wherein said anti-Helicobacter pylori action substance is selected from the group consisting of penicillins antibiotic, macrolide antibiotic and combinations thereof.